**Core tip:** Inflammatory bowel disease (IBD) has multiple etiologies, including genetic and environmental factors. Recent reports have described how some children with Wiskott-Aldrich syndrome (WAS) present IBD or IBD-like gastroenterocolitis. In this study, we found a *WAS* c.1378C\>T, p.Pro460Ser mutation in three children with IBD. These patients did not present typical symptoms of WAS, such as thrombocytopenia and recurrent infection. However, WAS is known to be associated with an increased risk of malignancies including lymphoma, as well as autoimmune diseases. Therefore, in any long-term follow-up, the analysis of WASP expression in children with IBD should be considered even if major symptoms of WAS are absent.

INTRODUCTION
============

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammatory disorder of the gastrointestinal tract. IBD is caused by multiple factors; genetics, epigenetics, environment, microbiota and immune responses\[[@B1]-[@B3]\]. Recently, it was discovered that some patients with primary immunodeficiencies initially develop IBD or IBD-like gastroenterocolitis, especially in childhood. IBD that occur in primary immunodeficiencies is likely to be refractory to conventional treatments and is often more prominent than the susceptibility to infection\[[@B4]\]. It has been reported that children with Wiskott-Aldrich syndrome (WAS) and chronic granulomatous disease (CGD) could develop IBD or IBD-like gastroenterocolitis\[[@B5]\]. WAS is an X-linked disorder characterized by the triad of thrombocytopenia with small platelets, eczema, and recurrent infection. X-linked thrombocytopenia (XLT) is a milder form of WAS characterized by isolated thrombocytopenia. In WAS cases, gastrointestinal inflammation mimicking UC has occasionally been documented\[[@B5]-[@B7]\]. CGD is caused by defective phagocyte superoxide generation leading to impaired microbial killing, in which gastrointestinal inflammation mimicking CD has also occasionally been documented\[[@B5],[@B8]-[@B10]\]. In this study, we analyzed WAS and CGD in children with IBD and described their clinical features. WAS and CGD are among the more common monogenic primary immunodeficiencies, for the diagnosis of which rapid methods using flow cytometry have been established\[[@B11],[@B12]\]. Therefore, these two diseases were selected for this study. The diagnosis of underlying primary immunodeficiencies is important for investigating the pathogenesis of IBD, selecting appropriate treatment, taking precautions regarding malignancies and autoimmune diseases, and performing genetic counseling.

MATERIALS AND METHODS
=====================

Patients and methods
--------------------

Patients with childhood-onset IBD, which developed earlier than at 17 years old and was consistent with the Paris classification A1a + A1b\[[@B13]\], were recruited from Saiseikai Yokohama-shi Tobu Hospital, Yokohama, Japan, between July 2015 and July 2016. All patients had already been diagnosed with IBD prior to recruitment into this study. The diagnosis and classification of IBD were made based on clinical, endoscopic, radiological, and histological findings, in accordance with the Revised Porto Criteria\[[@B14]\]. IBD was classified into three disease entities: CD, UC, and IBD-unclassified (IBD-U). Blood samples were collected from patients after obtaining written informed consent from their parents or guardians, and also collected from healthy young adults as a control. This study was performed in accordance with the Declaration of Helsinki and approved by the institutional ethics committees of Yokohama City University School of Medicine and Saiseikai Yokohama-shi Tobu Hospital (number: A140724004).

For initial screening, flow cytometric analysis was performed to evaluate the expression of Wiskott-Aldrich syndrome protein (WASP) in lymphocytes and superoxide generation in phagocytes. Patients' white blood cells were analyzed using an EC800 flow cytometry analyzer (Sony Biotechnology, Tokyo, Japan). Forward scatter and side scatter were collected in linear mode to gate lymphocytes and neutrophils. Genetic analysis of the *WAS* gene was performed upon the discovery of low or absent expression of WASP.

WASP analysis
-------------

Intracellular staining of WASP was performed in accordance with a previously described method\[[@B12],[@B15]\]. Whole blood was separated into peripheral blood mononuclear cells (PBMCs) by Lymphoprep® (Axis-Shield PoC AS, Oslo, Norway). The PBMCs were fixed in a fixation buffer (BD Biosciences Pharmingen, San Diego, CA, United States) for 15 min at room temperature, and then permeabilized in Perm/Wash buffer (BD Biosciences Pharmingen). They were then incubated with a rabbit anti-WASP monoclonal antibody (Abcam, Cambridge, United Kingdom) for 30 min at 4 °C. After washing, they were incubated with an Alexa Fluor 488-conjugated anti-rabbit IgG Fab2 fragment (Cell Signaling Technology, Danvers, MA, United States) for 30 min at 4 °C. The PBMCs were then washed again and centrifuged at 1500 × *g* for 1 min, twice. The obtained pellets were then resuspended in buffer and immediately analyzed by flow cytometry.

DHR123 assay
------------

The DHR123 assay was performed in accordance with a previously described method\[[@B16]\]. Whole blood (100 μL) and 1 mL of 0.1 mmol/L DHR123 (Lambda Fluoreszenz Technologie GmbH, Vienna, Austria) were added to each tube. The tubes were incubated at 37 °C for 15 min to stain the phagocytes with DHR123. After incubation, 25 mmol/L ethylenediaminetetraacetic acid and 25 μg/mL phorbol myristate acetate (Sigma-Aldrich, St. Louis, MO, United States) were added to each tube. The tubes were incubated again at 37 °C for 20 min. They were then centrifuged at 400 × *g* for 5 min and the supernatant was discarded. Lysis buffer was added to the tubes. After 15 min, the tubes were centrifuged at 400 × *g* for 5 min and the supernatant was discarded. Subsequently, the pellets were suspended in buffer and immediately analyzed by flow cytometry.

Gene mutation analysis
----------------------

*WAS* gene analysis was performed for all patients who showed normal and low expression of WASP. Genomic DNA was extracted from peripheral blood leukocytes using a QIAamp® DNA Blood Mini Kit (QIAGEN, Hilden, Germany). Polymerase chain reaction (PCR) primer sequences were derived from previous reports\[[@B17],[@B18]\]. PCR was performed with a thermal cycler under the following conditions: initial denaturation at 94 °C for 5 min; then 32 cycles with denaturation at 94 °C for 1 min, annealing at 55-60 °C for 1 min, and extension at 72 °C for 1 min; and then final extension at 72 °C for 10 min. Each PCR product was electrophoresed on an agarose gel to confirm its size. To determine its DNA sequence, direct sequencing was performed using an Applied Biosystems 3730xl DNA Analyzer and Sequence Scanner version 1.0 software (Applied Biosystems, Waltham, MA, United States), under the conditions recommended by the manufacturer. *In silico* analysis of the mutated *WAS* sequence was performed using PolyPhen-2 (Polymorphism Phenotyping V.2, <http://genetics.bwh.harvard.edu/pph2/dbsearch.shtml>) and SIFT (<http://sift.jcvi.org/>) in addition to a literature review of the mutated gene sequence.

RESULTS
=======

Patient characteristics
-----------------------

Eighteen patients were enrolled in this study, the characteristics of whom are summarized in Table [1](#T1){ref-type="table"}. Ten patients were classified as having UC, five as CD, and three as IBD-U. The median ages at first presentation of clinical symptoms for these three groups were 9.5, 12.0, and 6.0 years old, respectively. In five patients, age at the onset was 6 years or younger and they classified into very early onset IBD (VEOIBD)\[[@B19]\]. One patient with CD had refractory eczema, but no patients developed thrombocytopenia or susceptibility to infection suggestive of WAS or CGD.

###### 

Characteristics of patients with childhood-onset inflammatory bowel disease in this study (*n* = 18)

  **Disease**                              **UC**       **CD**        **IBD-U**
  ---------------------------------------- ------------ ------------- -----------
  *n*                                      10           5             3
  Sex (male, female)                       8, 2         4, 1          1, 2
  Median age at onset in yr (range)        9.5 (1-13)   12.0 (6-13)   6.0 (1-9)
  Symptoms (number of positive patients)                              
  Diarrhea                                 10           5             1
  Mucosal aphthae                          1            2             0
  Eczema                                   0            1             0
  Skin abscesses                           0            0             0
  Thrombocytopenia                         0            0             0
  Recurrent infection                      0            0             0

UC: Ulcerative colitis; CD: Crohn's disease; IBD-U: Inflammatory bowel disease-unclassified.

WASP analysis, DHR123 assay, and genetic analysis
-------------------------------------------------

WASP expressions of healthy controls were normal. Three patients (UC, *n* = 2; CD, *n* = 1) showed low expression of WASP compared with the healthy controls (Figure [1A](#F1){ref-type="fig"}), but no patients showed a complete lack of WASP expression. Subsequent *WAS* gene analysis revealed the same mutation (c.1378C\>T, p.Pro460Ser) in all three patients (Figure [1B](#F1){ref-type="fig"}). This mutation is located in the verprolin, cofilin, and acidic domain in exon 11 of the *WAS* gene. Additionally, this mutation was not found in any of 15 patients with normal expression of WASP. We performed *in silico* analysis of the mutation using PolyPhen-2 and SIFT, in addition to a literature review. PolyPhen-2 suggested that this is a benign mutation, while SIFT suggested that it is a tolerated one. However, in the literature review, we found four patients with typical WAS (*n* = 1) or XLT (*n* = 3) sharing the same c.1378C\>T, p.Pro460Ser mutation of the *WAS* gene, who exhibited low expression of WASP (Table [2](#T2){ref-type="table"})\[[@B20]-[@B23]\]. DHR123 assays revealed no patients with abnormal superoxide generation. Therefore, no patients were diagnosed with CGD.

![Analysis of Wiskott-Aldrich syndrome protein in patients' lymphocytes (A). Histograms represent intracellular Wiskott-Aldrich syndrome protein (WASP) staining (shaded area) and negative staining (unshaded area). Three patients with childhood-onset IBD presented low expression of WASP compared with that in the healthy control. B: *WAS* gene analysis. The three patients who showed low expression of WASP had the same mutation, c.1378C\>T p.Pro460Ser.](WJG-23-8544-g001){#F1}

###### 

Previous reports of the c.1378C\>T, p.Pro460Ser mutation of *WAS*

  **Phenotype**   **Sex**   **Age at onset**   **Platelet (×10^3^/μL)**   **WASP expression**   **Ref**.
  --------------- --------- ------------------ -------------------------- --------------------- ---------------------------------------------------------
  XLT             M         8 mo               65-100                     low                   Lutskiy et al\[[@B20]\]
  XLT             M         4 d                low                        low                   Lee et al\[[@B21]\]
  WAS             M         N.D.               low                        N.D.                  Gulácsy et al\[[@B22]\][1](#T2FN1){ref-type="table-fn"}
  XLT             M         6 yr               5                          low                   Ouchi-Uchiyama et al\[[@B23]\]

This patent has double mutation (p.Pro460Ser and p.Met474Thr). ND: No data; XLT: X-linked thrombocytopenia; WAS: Wiskott-Aldrich syndrome; WASP: Wiskott-Aldrich syndrome protein.

Clinical course of three patients with WAS mutation
---------------------------------------------------

The clinical features of the three patients with the *WAS* mutation are summarized in Table [3](#T3){ref-type="table"}. Patient 3 was classified into VEOIBD. Although all three patients had diarrhea, none of them showed either thrombocytopenia or increased susceptibility to infection, two of the major symptoms of WAS and XLT. Their mean platelet volumes were within the normal range. Only Patient 1 showed eczema, one of the major symptoms of WAS. Interestingly, this eczema was markedly exacerbated after the initiation of tumor necrosis factor alpha (TNFα) blockade treatment (Figure [2](#F2){ref-type="fig"}), but immediately improved upon its discontinuation. At the time of writing, none of these patients has developed other autoimmune diseases or malignancies. Additionally, no patients have a family history suggestive of WAS.

![Cutaneous manifestations of Patient 1 (scaling eczema and pigmentation).](WJG-23-8544-g002){#F2}

###### 

Clinical features of three patients with *WAS* c.1378C\>T, p.Pro460Ser mutation

  **Patient**   **Sex**   **Diagnosis**   **Age at onset**   **Clinical symptoms**            **Platelet count (× 10^3^/μL) /mean platelet volume (fl)**   **Present status and treatment**
  ------------- --------- --------------- ------------------ -------------------------------- ------------------------------------------------------------ ---------------------------------------------------
  Patient 1     M         CD              12 yr              Fever, Eczema, Watery diarrhea   431/8.9                                                      Remission mesalazine, azathioprine and infliximab
  Patient 2     M         UC              11 yr              Mucous-bloody diarrhea           220/10.4                                                     Remission mesalazine and azathioprine
  Patient 3     M         UC              2 yr               Mucous-bloody diarrhea           339/9.4                                                      Remission mesalazine and prednisolone enema

UC: Ulcerative colitis; CD: Crohn's disease; mean platelet volume (fl), normal 8.9-12.6.

Endoscopic findings in these three patients were consistent with those of typical CD or UC. Patient 1 had long linear ulcerations and cobble stone appearance in the ileum to the colon (Figure [3A](#F3){ref-type="fig"}). Patient 2 showed edematous and friable mucosa with superficial bleeding in the descending colon and sigmoid colon (Figure [3B](#F3){ref-type="fig"} and C). Patient 3 had edematous mucosa with granularity and erythema in the rectum from the sigmoid colon to the rectum (Figure [3D](#F3){ref-type="fig"}) and inflammatory polyps in the sigmoid colon. All three patients had successfully achieved remission with the medications shown in Table [3](#T3){ref-type="table"}.

![Endoscopic findings in the patients with WAS c.1378C\>T, p.Pro460Ser mutation. A: Patient 1: long linear ulcerations and cobble stone appearance in the ileum. B and C: Patient 2: edematous and friable mucosa with superficial bleeding in the descending colon and sigmoid colon. D: Patient 3: edematous mucosa with granularity and erythema in the rectum.](WJG-23-8544-g003){#F3}

DISCUSSION
==========

In infants and children, primary immunodeficiencies such as common variable immunodeficiency, CGD, IL-10 signaling defects, X-linked lymphoproliferative syndrome type 2, immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome and WAS could present as IBD or IBD-like colitis\[[@B24]-[@B29]\]. Recently, genome-wide association studies of IBD have identified 163 genetic loci\[[@B30]\] and 50 monogenic disorders including primary immunodeficiency associated with IBD-like immunopathology\[[@B19]\]. Underlying primary immunodeficiency may easily be missed by clinicians. Cannioto et al\[[@B5]\] reported one CGD and three WAS patients among 16 children with IBD diagnosed before 2 years of age. However, their clinical symptoms were typical of WAS and CGD.

In this study, we investigated children with IBD to screen underlying WAS and CGD. As a result, we found three patients with a *WAS* c.1378C\>T, p.Pro460Ser mutation, but found none with CGD using flow cytometry. WAS is an X-linked disorder characterized by the triad of thrombocytopenia with small platelets, eczema, and recurrent infection. *WAS* gene mutations are associated with a wide spectrum of disease, from typical WAS to XLT characterized by isolated thrombocytopenia\[[@B31],[@B32]\]. Generally, clinical manifestations correlate with the level of WASP expression. Classical WAS tends to be associated with the complete absence of WASP, whereas incomplete WAS and XLT are likely to be associated with low or absent expression. However, the phenotype does not always reflect the genotype of *WAS* mutations. Although *in silico* analysis suggested that the *WAS* c.1378C\>T, p.Pro460Ser mutation would not be pathogenic, the mutation detected in our patients was previously reported in four patients with typical WAS or XLT\[[@B29]-[@B32]\] (Table [2](#T2){ref-type="table"}). One of them had double mutations (p.Pro460Ser and p.Met474Thr). Three of them showed low WASP expression, but none developed IBD or IBD-like colitis. In contrast, our patients did not show thrombocytopenia or recurrent infection despite low WASP expression in their lymphocytes. Only one patient showed refractory eczema. Eczema in WAS is known as an atopic dermatitis-like manifestation. This patient's cutaneous manifestation was atopic dermatitis-like eczema at onset, which then shifted to scaling eczema and pigmentation (Figure [2](#F2){ref-type="fig"}). His eczema was exacerbated by TNFα blockade treatment, but improved rapidly upon its discontinuation. TNFα blockade frequently causes cutaneous complications such as vasculitis and eczema in patients with IBD. Scaling eczema is the most common cutaneous complication in adults, while psoriasis-like manifestations are most frequently seen in children\[[@B33],[@B34]\]. Our patient's eczema differed from the typical TNFα blockade-related cutaneous complications in children, but resembled those in adults. There may be possibility that *WAS* mutation is associated with TNFα blockade-cutaneous complication and prediction for the complication. Endoscopic findings in three patients were typical of CD or UC, and were not distinguishable between patients with the mutation and without it. Only one of five VEOIBD patients in our study showed low expression of WASP and *WAS* mutation. VEOIBD patients often have different symptoms from older children and adults with IBD\[[@B25]\]. In general, genetics is suggested to be an important factor in VEOIBD\[[@B35]\]. *WAS* mutation might be associated with pathogenesis of VEOIBD. In the ExAC database (exac.broadinstitute.org), the frequency of *WAS* c.1378C\>T, p.Pro460Ser mutation is 0.03817 in East Asians, and it appears to be more common in East Asians than in other ethnic groups. The frequency of this mutation in this study is 0.1667 (3/18), which is much higher than in East Asians. Therefore, *WAS* c.1378C\>T, p.Pro460Ser mutation could be a risk factor for IBD development.

Patients with a *WAS* mutation are likely to develop autoimmune diseases, with up to 40% developing hemolytic anemia, neutropenia, vasculitis, IBD/IBD-like colitis, or renal disease\[[@B5],[@B9],[@B10],[@B36]\]. The incidence of autoimmune diseases in XLT is lower than in typical WAS\[[@B37]\]. However, Imai et al\[[@B38]\]. reported that autoimmune diseases are equally common in patients with absent versus low expression of WASP\[[@B38]\]. Precaution for new-onset autoimmune diseases is important in our patients.

Snapper et al\[[@B39]\] reported that WASP-deficient mice developed chronic colitis. The colons of these mice were diffusely dilatated and had mucosal thickening due to crypt hyperplasia and the presence of mixed lymphocytic and neutrophilic infiltrate within the lamina propria\[[@B39]\]. WASP is expressed in the cytoplasm of hematopoietic cells. It acts as a signal transducer from cell surface receptors, and also plays essential roles in cell-cell interactions, cell movement, and cell division\[[@B40],[@B41]\]. WASP dysfunction, leading to impaired regulatory T cells and expansion of autoreactive B cells\[[@B42],[@B43]\], may provoke autoimmune diseases including IBD/IBD-like colitis\[[@B44]\]. The impaired regulatory T cells caused by WASP dysfunction also affect microbiota, which may lead to IBD/IBD-like colitis. Above all, WASP analysis may reveal the possible risk of new-onset autoimmune diseases.

Patients with typical WAS also have an increased risk of malignancies: 12%-30% of patients suffer from them, among which B-cell lymphoma is particularly common. Because there have been few reports of malignancies in patients with XLT, their incidence is presumably lower in XLT than in WAS\[[@B37],[@B45],[@B46]\]. However, TNFα blockade and azathioprine, which are the main treatments for refractory IBD, significantly increase the risk of lymphoma\[[@B47]-[@B49]\]. Thus, careful monitoring in patients with *WAS* mutation is necessary, especially under these two treatments.

This study has several limitations, including the small number of patients and the fact that it is a single-center study. Additional study with a greater number of patients is thus now underway. Further functional analysis to examine whether the *WAS* c.1378C\>T, p.Pro460Ser mutation affects thrombocytosis and lymphocyte function is needed, although this mutation has previously been reported in some patients with WAS or XLT. In addition, there is a need for the screening of other primary immunodeficiencies known to be associated with the presentation of IBD or IBD-like gastroenterocolitis.

In conclusion, we found a *WAS* c.1378C\>T, p.Pro460Ser mutation in three children with IBD, the lymphocytes of whom exhibited low WASP expression. We suggest that low WASP expression has an association with the development of IBD/IBD-like colitis. Therefore, the analysis of WASP expression in children with IBD should be considered even if the triad of WAS symptoms is absent. Screening for underlying immunodeficiencies including WAS and CGD may contribute to improving patient management and outcome. Especially, physicians can pay more attention to the increased future risk of malignancy and autoimmune disease in IBD patients with WAS mutation.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammatory disorder of the gastrointestinal tract. Recently, it was discovered that some patients with primary immunodeficiencies initially develop IBD or IBD-like gastroenterocolitis, especially in childhood.

Research motivation
-------------------

Children with Wiskott-Aldrich syndrome (WAS) and chronic granulomatous disease (CGD) could develop IBD or IBD-like gastroenterocolitis. The diagnosis of underlying primary immunodeficiencies such as WAS and CGD is important for investigating the pathogenesis of IBD, selecting appropriate treatment, taking precautions regarding malignancies and autoimmune diseases, and performing genetic counseling.

Research objectives
-------------------

To screen primary immunodeficiency, WAS and CGD, among children with inflammatory bowel disease (IBD), and to investigate their clinical features.

Research methods
----------------

This was a single-center retrospective study. Eighteen children with IBD were investigated. We performed intracellular staining of Wiskott-Aldrich syndrome protein (WASP) to analyzed their expression in lymphocytes and DHR123 assay to analyze superoxide generation in phagocytes using flow cytometry. When the expression of WASP or superoxide generation was low or absent, we performed direct DNA sequence to determine the cause of this. *In silico* analysis was performed using PolyPhen-2 (Polymorphism Phenotyping V.2, <http://genetics.bwh.harvard.edu/pph2/dbsearch.shtml>) and SIFT (<http://sift.jcvi.org/>), in addition to a literature review of the mutated gene sequence.

Research results
----------------

DHR123 assays revealed no patients with abnormal superoxide generation. Three patients (UC, *n* = 2; CD, *n* = 1) showed low expression of WASP compared with the healthy controls. *WAS* gene analysis revealed the same mutation (c.1378C\>T, p.Pro460Ser) in all three patients. The mutation was previously reported in four patients with typical WAS or XLT. But, *in silico* analysis suggested that the mutation would not be pathogenic. Our patients with the mutation did not show thrombocytopenia or recurrent infection despite low WASP expression in their lymphocytes. Only one patient showed refractory eczema.

Research conclusions
--------------------

We found a *WAS* c.1378C\>T, p.Pro460Ser mutation in three children with IBD, the lymphocytes of whom exhibited low WASP expression. We suggest that low WASP expression has an association with the development of IBD/IBD-like colitis. Therefore, the analysis of WASP expression in children with IBD should be considered even if the triad of WAS symptoms is absent.

Research perspectives
---------------------

In this study, we found a *WAS* c.1378C\>T, p.Pro460Ser mutation in three children with IBD. These patients did not present typical symptoms of WAS, such as thrombocytopenia and recurrent infection. However, WAS is known to be associated with an increased risk of malignancies including lymphoma, as well as autoimmune diseases. Therefore, in any long-term follow-up, the analysis of WASP expression in children with IBD should be considered even if major symptoms of WAS are absent.
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